Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
AmerisourceBergen acquires World Courier Group

AmerisourceBergen acquires World Courier Group

FANCM gene plays key role in recombination of genetic information during inheritance

FANCM gene plays key role in recombination of genetic information during inheritance

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

UAB researcher wins HudsonAlpha Prize for work on sickle cell and related blood disorders

Maternal stress during first trimester of pregnancy puts newborns at risk for iron deficiency

Maternal stress during first trimester of pregnancy puts newborns at risk for iron deficiency

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

MSF says number of annual malaria cases treated in DRC has tripled since 2009

MSF says number of annual malaria cases treated in DRC has tripled since 2009

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

Medgenics seeks FDA Orphan Drug Designation for INFRADURE to treat hepatitis D

EMA CHMP recommends approval of AMAG’s ferumoxytol

EMA CHMP recommends approval of AMAG’s ferumoxytol

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

Positive results from Alnylam’s ALN-PCS Phase I trial on severe hypercholesterolemia

New wiki of medical devices designed for resource-limited settings

New wiki of medical devices designed for resource-limited settings

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Final results from MSD’s VICTRELIS plus PEGINTRON Phase III trial on HCV treatment-related anemia

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Medgenics seeks IND approval to initiate EPODURE Biopump Phase IIb anemia study in ESRD patients

Study calls for research into all aspects of follow-up care in lung cancer

Study calls for research into all aspects of follow-up care in lung cancer

The key to treating AML may lie within FTL3 gene mutations

The key to treating AML may lie within FTL3 gene mutations

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

FDA approval of OMONTYS triggers $50M milestone payment to Affymax

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Spectrum signs definitive agreement to acquire Allos

Spectrum signs definitive agreement to acquire Allos

ASN participates in ABIM Foundation's Choosing Wisely campaign

ASN participates in ABIM Foundation's Choosing Wisely campaign

Infections in older adults may increase risk of hospitalization for dangerous blood clots

Infections in older adults may increase risk of hospitalization for dangerous blood clots

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

Nektar commences dosing in NKTR-192 Phase 1 clinical study for treatment of acute pain

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.